RecruitingHematopoietic and Lymphatic System NeoplasmAcute Lymphobkastic Leukemia
A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
Eligible age
1+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Followed by pediatric hematology/oncology
- ✓ Receiving recombinant Erwinia asparaginase for treatment of malignancy
You may not qualify if…
- ✕ Patients \< 1 year of age
- ✕ Patients who have previously received recombinant Erwinia asparaginase within the past two weeks
Where it's recruiting
Minnesota
Rochester
Source: ClinicalTrials.gov · NCT06600659 · last updated 2026-02-06